Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
First Claim
1. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising:
- providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;
administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and
inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease that involves providing an individual with an effective amount of a composition of bacteria modified using a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system so that the bacteria is able to produce a therapeutically effective amount of anti-bodies to oxidized low density lipoprotein, with the modified bacteria preferably being from the Lactobacillus, Bifidobacterium, and Streptococcus species; and most preferably including L. reuteri bacteria modified using CRISPR-Cas and/or Cpf1 systems so that it is able to survive the conditions in the duodenum and jejunum of the small intestine of a human.
147 Citations
13 Claims
-
1. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising:
- providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;
administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and
inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production. - View Dependent Claims (2, 3, 4, 5)
- providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;
-
6. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising:
- providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;
administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and
inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual. - View Dependent Claims (7, 8, 9)
- providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;
-
10. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising:
- providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;
administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and
increasing the levels of Roseburia, while reducing the levels of Akkermansia spp. in the individual'"'"'s gut microbiome. - View Dependent Claims (11, 12, 13)
- providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species;
Specification